Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC

BACKGROUND: Nivolumab is an immune checkpoint inhibitor targeting the programmed death-1 receptor that improves survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). In contrast to other tumor types that respond to immunotherapy, factors such as programmed death ligand-1 (PD...

Descripción completa

Detalles Bibliográficos
Autores principales: Ross-Macdonald, Petra, Walsh, Alice M, Chasalow, Scott D, Ammar, Ron, Papillon-Cavanagh, Simon, Szabo, Peter M, Choueiri, Toni K, Sznol, Mario, Wind-Rotolo, Megan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931766/
https://www.ncbi.nlm.nih.gov/pubmed/33658305
http://dx.doi.org/10.1136/jitc-2020-001506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931766/
https://www.ncbi.nlm.nih.gov/pubmed/33658305
http://dx.doi.org/10.1136/jitc-2020-001506

Ejemplares similares